Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Rachna Saralkar

Psychiatry Oakland, CA Medical Doctor

NPI 1376832162 CMS profile 1228007

2616 Harrison St Apt 1, Oakland, CA 94612

Open in the dashboard

General payments

$2,502

167 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Rachna Saralkar of Oakland, CA is reported in the CMS Open Payments database as having received $2,502 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $56 2
2022 General $101 5
2021 General $23 1
2020 General $387 20
2019 General $1,937 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachna Saralkar
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rachna Saralkar were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rachna Saralkar Psychiatry median Middle half National median
2019 $1,937 $184 $59–$605 $163
2020 $387 $119 $36–$372 $114
2021 $23 $143 $43–$576 $132
2022 $101 $153 $50–$590 $149
2023 $56 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $419 18 payments
  2. Allergan Inc. $410 38 payments
  3. Otsuka America Pharmaceutical, Inc. $294 23 payments
  4. Vanda Pharmaceuticals Inc. $239 13 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $233 14 payments
  6. Teva Pharmaceuticals USA, Inc. $193 11 payments
  7. Shire North American Group Inc $183 10 payments
  8. Lundbeck LLC $151 13 payments
  9. Neurocrine Biosciences, Inc. $86 4 payments
  10. AbbVie, Inc. $58 3 payments
  11. Other $237 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,471 165 payments
  2. Education $32 2 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR $386 36 payments
  2. SPRAVATO $369 16 payments
  3. INVEGA SUSTENNA $254 11 payments
  4. VYVANSE $243 13 payments
  5. FANAPT $239 13 payments
  6. HETLIOZ $237 12 payments
  7. REXULTI Psychiatry $201 17 payments
  8. AUSTEDO $193 11 payments
  9. Trintellix $136 9 payments
  10. REXULTI Psychiatry $100 8 payments
  11. Other $788 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

719

Median for Psychiatry: 574

Drug cost

$16,833

Median for Psychiatry: $27,624

Branded share of claims

15.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 12 $2,397
Aripiprazole Generic 17 $2,017
Duloxetine Hcl Generic 58 $1,802
Bupropion Xl Bupropion Hcl Brand 56 $1,437
Quetiapine Fumarate Generic 53 $1,036
Gabapentin Generic 59 $907
Mirtazapine Generic 57 $893
Trazodone Hcl Generic 61 $772
Clonazepam Generic 62 $693
Fluoxetine Hcl Generic 43 $684

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$42,562

Medicare's payments for the services billed

Medicare patients

56

Average age 73

Services billed

490

44 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 71%
Arthritis 54%
Diabetes 27%
Chronic kidney disease 25%
Cancer 23%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record